The effect of intratympanic steroid injection frequency in idiopathic sudden sensorineural hearing loss

Purpose

To evaluate the effect of intratympanic steroid injection frequency on hearing outcomes for patients with idiopathic sudden sensorineural hearing loss.

Intratympanic steroids in severe to profound sudden sensorineural hearing loss as salvage treatment

Objectives

Intratympanic steroids are being increasingly used in the treatment of sudden sensorineural hearing loss (SSNHL) after the failure of systemic therapy. This study evaluated the efficacy of administering intratympanic dexamethasone (ITD) as a salvage treatment for severe to profound SSNHL.

Methods

We reviewed the medical records of patients who presented with severe to profound SSNHL between January 2007 and December 2009. ITD was given about 14 days after the initial systemic treatment. Successful recovery was defined as complete or partial recovery using Sigel''s criteria. We compared the results of treatment between the severe SSNHL (S-SSNHL) and profound SSNHL (P-SSNHL) groups.

Results

All the patients in the S-SSNHL group showed significant improvement, as compared to the P-SSNHL group (P=0.017). The recovery rate after the initial systemic treatment was 36% (9/25) in the S-SSNHL group and 18.1% (4/22) in the P-SSNHL group (P=0.207). In comparison, the recovery rate of ITD as a salvage treatment was 37.5% (6/16) in the S-SSNHL group and 5.5% (1/18) in the P-SSNHL group (P=0.03).

Conclusion

Our comparative study dose not support the efficacy of ITD as salvage treatment for patients with P-SSNHL as compared with that for S-SSNHL. We recommend that patients with P-SSNHL be informed about the low efficacy of ITD as a salvage treatment.     

突发性耳聋伴眩晕患者听力预后分析

摘要：目的回顾性分析突发性耳聋（sudden deafness,SD）患者的听力损失程度、预后与发病时是否伴有眩晕发作的关系。探索突发性耳聋单发听力损失、突发性耳聋伴眩晕的诊断、治疗及预后评价。 方法按中华医学会耳鼻咽喉头颈外科学分会颁布的突发性耳聋诊断标准,2012年1月~2015年12月收治突发性耳聋患者196例。对所有患者进行扩管溶栓、营养神经、抗病毒及高压氧治疗,按2007年中华耳鼻咽喉学会颁布的突发性耳聋疗效及分级标准,针对听力恢复进行疗效评价。结果伴有眩晕症状患者发病率为30.7%,听力损失在50 dB以上,听力恢复有效率23%;不伴有眩晕症状患者发病率为69.3%,听力恢复有效率73%。结论伴发眩晕的突发性耳聋患者,往往其听力损失严重,且预后不佳。     

鼓室注射甲泼尼龙琥珀酸钠治疗突聋

目的观察甲泼尼龙琥珀酸钠鼓室途径给药治疗系统疗法无效的突发性聋患者的疗效,探索突聋预后影响因素。方法经全身系统治疗无效的突聋患者42例,采用鼓膜穿刺法注入40mg／ml甲泼尼龙琥珀酸钠0．3-0．5ml,隔日1次,连续应用3-7次。比较鼓室注射前后0．5-4kHz气导纯音听阈均值差异,分析相关因素对预后的影响。结果鼓室内注射疗法治疗前后,全组病例气导平均听阂分别为（66．48±17．03）dBHL和（49．9±20．93）dBHL,治疗前后平均听阈差异明显（P〈0．01）;其中19例有效,总有效率为45．2％。听力损失程度、伴有眩晕与否及发病后鼓室注射疗法开始时间等因素对预后影响明显。结论甲泼尼龙琥珀酸钠鼓室注射疗法治疗突聋安全有效,可以作为经全身系统治疗无效突聋患者的后续治疗选择。一般治疗无效者,应尽早采用本疗法。     

耳后药物注射治疗突发性聋32例

目的 观察耳后注射糖皮质激素治疗突发性聋的疗效.方法 65例突聋患者分为耳后注射组(32例)和鼓室给药组(33例),除常规治疗外,两组分别经耳后注射和鼓膜穿刺给予地塞米松0.5 mg,1次/3 d,疗程14 d.结果 耳后注射组和鼓室给药组听力改善分别为(13.2±8.6)dB和(14.6±11.1)dB,两组治疗前后比较差异均有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05),不良反应试验组低于对照组(P<0.05).结论 突聋患者耳后局部注射糖皮质激素效果明显、操作简单、不良反应低,可作为鼓室给药有禁忌时的备选疗法.     

鼓室置管灌注甲泼尼龙治疗难治性突发性聋的听力疗效再分析

目的 探讨经耳道鼓室置管灌注甲泼尼龙治疗难治性突发性聋(sudden sensorineural hearing loss,SSNHL)的安全性和有效性.方法 对常规治疗至少一个疗程(10天)无效的SSNHL,根据病人的意愿分成灌注组和对照组分别继续治疗10天.灌注组给予鼓室置管灌注甲泼尼龙+常规治疗,对照组继续常规治疗,比较治疗结束后3个月时两组的听力改善结果.结果 灌注组26例和对照组23例,两组的有效率分别是50.0%和21.7%,继续治疗前后PTA改善分别是16.7 dB和9.2 dB,两组比较灌注组的有效率高于对照组(P=0.041); 若仅将发病至继续治疗的时间间隔≤60天的病例纳入分析,则灌注组为21例,对照组仍为23例,有效率分别是61.9%和21.7%,PTA改善分别为20.2 dB和9.2 dB,灌注组均优于对照组(P_(有效率)=0.007,P_(PTA 改善)=0.011);鼓室灌注前后低频区(0.25 kHz,0.5 kHz)、中频区(1 kHz、2 kHz)和高频区(4 kHz、8 kHz)的听阈分别改善19.8 dB、16.0 dB和13.4 dB,低频区听力改善大于高频区(P=0.046).结论 鼓室置管灌注甲泼尼龙联合常规治疗用于难治性SSNHL是安全的、有效的,疗效优于继续常规治疗,且低频区的听力改善优于高频区,发病后宜尽早采用.     

妊娠期突发性聋的临床特点及预后

目的分析妊娠期突发性聋的临床特点及预后,并探讨其治疗方案,提高临床医师对该病的认识。方法收集2013年1月~2017年1月在南华大学附属第一医院诊断并住院治疗的16例妊娠期突发性聋患者的一般临床资料。16例患者均为单侧发病,左侧8耳,右侧8耳;3例妊娠早期发病,7例妊娠中期发病,6例妊娠晚期发病;10例伴有耳鸣,4例伴有眩晕,患者入院平均听阈为（64.45±27.83 ）dBHL,所有患者入院后均予低分子右旋糖酐静脉滴注及鼓室内注射地塞米松治疗。结果治疗后平均听阈为（46.48±29.81）dBHL,平均听阈改善值为（17.34±15.70） dBHL,与治疗前比较差异具有统计学意义（P<0.05）。痊愈5耳,显效2耳,有效6耳,无效3耳。结论妊娠期突发性聋常发病于妊娠中晚期,听力损失较重且常伴有耳鸣,听力曲线以全聋型和平坦型为主;给予鼓室内注射地塞米松联合低分子右旋糖酐静脉滴注治疗安全有效。     

鼓室灌注地塞米松治疗难治性突发性感音神经性聋临床分析

目的观察和比较鼓膜穿刺、鼓膜置管和圆窗置管微泵灌注地塞米松3种方法治疗难治性突发性感音神经性聋的疗效。方法55例常规方法治疗无效的突聋患者作为研究对象,其中圆窗置管微泵灌注用药治疗21例(置管组),每次2.5mg/0.5ml,维持1小时,每天两次,连续给药7天,总剂量35mg;鼓膜穿刺注药23例(穿刺组),首次剂量为2.5mg,此后,每2天重复注药1次(每次2.5mg),共4次,总剂量10mg;鼓膜切开置管滴药11例(滴药组),首次剂量为0.5%地塞米松0.5ml,经通气管滴入鼓室,每天重复滴药2次(每次2.5mg),共7天,总剂量32.5mg。同期常规方法治疗无效的32例突聋患者,且拒绝鼓室用药者随访作为对照(对照组),比较各组听力恢复及并发症情况。4组治疗前听力无显著差异(P>0.05)。结果治疗完成后1月纯音测听检查:置管组、穿刺组和滴药组平均PTA分别提高9dB、8.6dB和1.7dB,前2组明显高于对照组1.4dB(P<0.05),置管组8例(38.1%)听力改善约15～56dB,无效13例;穿刺组8例(34.8%)听力改善约16～54dB,无效15例;滴药组1例(9.1%)听力改善约26dB,无效10例;对照组3例(9.4%)听力改善约15～36dB,无效29例。结论鼓室灌注地塞米松治疗难治性突聋方法安全有效,为用常规方法治疗无效的突聋患者,提供了再次治疗的机会。     

鼓室内灌注得宝松和地塞米松治疗突发性聋疗效比较

目的比较观察鼓室内灌注得宝松和地塞米松治疗突发性聋的疗效。方法发病1～15天内的突发性聋患者76例随机分成得宝松组40例及地塞米松组36例,分别应用相应药物进行鼓室灌注,每周2次,4次为1疗程。两组均同时加用低分子旋糖酐及能量合剂,疗程均为2周。结果得宝松组总有效率75.0%,地塞米松组总有效率44.4%,两组之间疗效差异有统计学义（P〈0.01）,而且病程与疗效之间亦有统计学意义（P〈0.05）。结论鼓室内灌注得宝松治疗突发性聋的疗效优于地塞米松鼓内灌注。     

鼓室激素注射为初始治疗的突发性聋听力恢复的时间规律

目的 探讨鼓室激素注射作为初始治疗突发性聋患者方案的听力恢复时间规律,寻求最佳鼓室给药时机。方法 将突发性聋患者135例纳入研究,均接受为期2周的全身激素治疗。其中63例仅接受全身激素治疗,另72例在全身激素治疗开始的同时联合鼓室内激素注射。所有病例随访2个月。结果 治疗后第3天、第7天、第14天、1个月、2个月每个时间点两组间总有效率差异均无统计学意义。全身激素治疗联合鼓室注射组第7天与第14天疗效差异无统计学意义(P=0.065),而单纯全身激素治疗者第7天与第14天疗效比较差异有统计学意义(P=0.029)。结论 鼓室激素注射联合全身激素治疗作为初始治疗方案,其疗效并不优于单纯全身激素治疗,但听力改善峰值的时间前者总体早于后者。     

A sudden bilateral hearing loss caused by inner ear hemorrhage

IntroductionLabyrinthine hemorrhage is a rare cause of sudden deafness and generally concerns only on one side.Case summaryAn 84-year-old man with a past medical history of myelomonocytic chronic leukemia (CMML) suffered from sudden bilateral hearing loss associated with vertigo. The audiogram revealed a left cophosis and a right profound deafness. Videonystagmography showed a left vestibular deficit. The MRI showed a spontaneous strong T1 weighted signal in the left and right labyrinths, corresponding to a bilateral inner ear hemorrhage (IEH). Dizziness resolved rapidly following vestibular physiotherapy, in contrast to hearing which did not improve at all and let the patient isolated in his environment. The patient successfully underwent cochlear implantation so that he could communicate.DiscussionMost IEHs are unilateral and due to anticoagulants treatments and hematological diseases. Only rare cases have described bilateral labyrinth hemorrhage. This is the first case reported of bilateral labyrinth hemorrhage due to CMML.     

突发性耳聋伴眩晕的临床分析

目的 探讨突发性耳聋(简称突聋)伴良性阵发性位置性眩晕(BPPV)或突聋伴眩晕综合征(非BP-PV)与突聋不伴眩晕的临床特征及疗效.方法 选取2018年1月-2019年12月收治的400例突聋患者,根据是否伴有眩晕症状,分为突聋伴眩晕组(163例)和突聋不伴眩晕组(237例)两组.163例突聋伴眩晕组患者进一步分为突聋...     

经咽鼓管鼓室途径注射地塞米松治疗突发性聋

目的 观察经咽鼓管鼓室注入地塞米松（简称PTIDI）治疗突发性聋（突聋）的疗效。方法 对18例常规方法治疗无效的突聋患者采用经咽鼓管鼓室径路注入地塞米松，首次剂量为5mg，此后，每天重复注药1次，每次5mg，共7次，总剂量35mg，用药期间密切观察记录听力改变，耳鸣和眩晕等情况。结果 18例患者于治疗完成后两周复查纯音测听。痊愈1例；显效5例，0．25-4kHz听阈平均提高50．2dB；有效1例，平均提高19dB；无效11例；有效率为38．9％（7／18）。结论 PTIDI治疗突聋疗效好，操作方便，避免全身用药可能产生的不良反应，为常规方法治疗无效的突聋患者提供了再次治疗的机会。     

鼓室内注射治疗难治性突发性耳聋52例

目的 探讨鼓室内注射激素作为难治性突发性耳聋的补救治疗措施的临床疗效。方法 重度及极重度突发性耳聋患者96例,接受常规治疗加全身应用激素2周效果不佳,其中52例接受鼓室注射激素,另外44例拒绝鼓室内注射而继续口服药物治疗。纯音测听法(PTA)检测患者补救治疗前后听力,比较气导听阈(0.5、1.0、2.0、4.0 kHz四个频率气导之平均值),分析两组患者补救治疗前后听力结果。结果 鼓室注射组听力提高10 dB以上的患者16例,有效率为30.8%;而对照组仅有3例,有效率为6.8%。两组听力改善值之间的差异有统计学意义(P<0.01)。结论 鼓室内激素注射对突发性耳聋常规治疗无效的患者有良好的疗效,可以作为一种补救治疗措施。     

Idiopathic sudden sensorineural hearing loss: Effectiveness of salvage treatment with low-dose intratympanic dexamethasone

Objectives:To evaluate hearing outcome of salvage treatment with intratympanic steroids(ITS)in idiopathic sudden sensorineural hearing loss(ISSNHL)refractory to initial systemic steroid(SS)therapy.Material and methods:A retrospective medical chart review was conducted on 54 consecutive patients with ISSNHL refractory to SS.Salvage treatment with a low dose intratympanic dexamethasone(4 mg/ml)was offered after one week of primary treatment.Patients were divided into two groups:25 patients accepted ITS(treatment group)and 29 patients did not undergo additional treatment(control group).A pure tone average(PTA)gain of at least 10 dB was considered hearing improvement.Results:Hearing improvement rate was higher in ITS group compared to control group(40%vs.13.8%,p=0.035).A mean PTA improvement of 8.6±9.8 dB was observed in the ITS group and,whereas the control group had an average hearing gain of 0.7±2 dB(p<0.001).Audiometric analysis revealed a significant hearing gain in ITS group at all tested frequencies compared to control group(p<0.05).Analysis of the selected variables,identified intratympanic steroid treatment as the only independent prognostic factor for hearing improvement(OR=4.2,95%CI:1.1e15.7;p=0.04).Conclusion:Intratympanic low dose dexamethasone is effective in patients with incomplete hearing recovery after primary systemic steroid treatment.     

强的松龙联合鼓室注射地塞米松治疗双耳突发性感音神经性聋临床疗效

目的本研究旨在分析注射强的松龙同时鼓室内注射地塞米松治疗双侧突发性感音神经性聋(SSNHL)的临床疗效。方法回顾性分析2007年3月至2020年3月就诊于我院同期治疗的双侧SSNHL病例。早期(2007年3月至2012年2月),这些病例仅用静脉注射泼尼松龙治疗,并分为A组。晚期(2012年2月至2020年3月),采用静脉强的松龙治疗联合鼓室内注射地塞米松治疗双侧SSNHL,这些患者被纳入B组。比较了A组和B组两种治疗方式的有效率。结果A组痊愈3耳,有效4耳,有效率为17.5%(7/40耳)。相比之下,B组痊愈6只,有效10只,有效率为36.4%(16/44只)。两组有效率有显著性差异。结论静脉注射强的松龙同时鼓室内注射地塞米松治疗双侧SSNHL是较好选择。     

Intratympanic vs systemic use of steroids as first-line treatment for sudden hearing loss: A meta-analysis of randomized,controlled trials

BackgroundSudden sensorineural hearing loss (SSNHL) is a common disease in otology, and steroids play an important role in its treatment. Steroids can be administered systemically or locally, and the efficacies of different administration routes remain controversial.MethodsWe searched the Cochrane, EMBASE, PubMed, Web of Science, CNKI, Wanfang and Weipu databases for randomized controlled trials (RCTs) on glucocorticoid treatments for SSNHL to compare the efficacy of topical and systemic steroid administration. The Review Manager 5.4 software was used for synthesis of data: the rate of reported hearing improvement and change in pure-tone audiometry (PTA).ResultsIn all the included studies, when intratympanic administration was compared to systemic therapies, the risk difference (RD) using reported hearing improvement as an outcome measure was 0.08 (95% CI: 0.01–0.14, I² = 45%). Using PTA changes as an outcome measure in 4 studies, the mean difference (MD) was 10.43 dB (95% CI: 3.68–17.18, I² = 81%). Hearing improvement RD was also compared among different types of steroid, recovery criteria, follow-up times and diagnostic criteria, and showed no significant differences exception for recovery criteria (>10 dB) (RD -0.06, 95% CI: 0.14-0.2, I² = 0%).ConclusionAs the initial treatment for SSNHL, topical steroids seem to be superior to systemic steroid administration, especially in patients with contraindications to systemic steroids usage. However, further verification based on high-quality research is needed.     

不同时机鼓室内注射糖皮质激素治疗重度以上突发性聋的疗效分析

目的 观察全身联合不同时机鼓室内注射糖皮质激素治疗重度以上突发性聋的疗效,探讨鼓室内注射时机,分析影响重度以上突发性聋预后的因素.方法 回顾性分析108例重度以上突发性聋患者的临床资料及治疗效果,其中全身联合初始鼓室组64例,全身联合延后鼓室组44例;对两组患者出院时与随访时疗效分别进行比较,并分析治疗有效组和无效组临...